Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Update on Phase III LEAP-012 trial in unresectable, non-metastatic hepatocellular carcinoma – Eisai + Merck

Written by | 11 Nov 2025

Eisai and Merck & Co., Inc., (known as MSD outside of the United States and Canada) announced results from that Phase III LEAP-012 trial evaluating Lenvima (lenvatinib), the… read more.

Agreement announced with U.S. Government to expand access to IVF-Therapies including Gonal-f, Ovidrel and Cetrotide – Merck

Written by | 31 Oct 2025

Merck KGaA announced that EMD Serono, their healthcare business of Merck in the U.S. and Canada, and U.S.-President Donald J. Trump’s administration entered into an agreement to expand… read more.

European Commission grants approval of Ogsiveo (nirogacestat) for treatment of desmoid tumors – Merck

Written by | 1 Oct 2025

Merck KGaA, announced that the European Commission (EC) granted marketing authorization for Ogsiveo (nirogacestat), an oral gamma secretase inhibitor, as monotherapy for the treatment of adults with progressing… read more.

NICE (UK) positive for Keytruda (pembrolizumab) in combination with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer – Merck

Written by | 25 Sep 2025

NICE (UK): Pembrolizumab with carboplatin and paclitaxel can be used, within its marketing authorisation, as an option for untreated primary advanced or recurrent endometrial cancer in adults. It… read more.

Positive CHMP opinion for Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) for pneumococcal vaccination in adults – Merck

Written by | 4 Aug 2025

Merck Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA recommended the approval of Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) for active immunization… read more.

FDA approves Welireg (belzutifan) to treat advanced, unresectable, or metastatic pheochromocytoma and paraganglioma – Merck Inc

Written by | 16 Jul 2025

Merck Inc., (known as MSD outside of the United States and Canada), announced the FDA  has accepted for priority review a supplemental new drug application (sNDA) seeking approval… read more.

ASCO 2025: Merck presents broad oncology data across 12+ tumor types

Written by | 27 May 2025

Merck, a leading science and technology company, announced the presentation of new oncology data across more than 12 tumor types at the 2025 American Society of Clinical Oncology… read more.

Merck to present new cardiovascular research at ACC.25, highlighting advances in PAH and cholesterol management

Written by | 24 Mar 2025

Merck known as MSD outside of the United States and Canada,  announced that new clinical and outcomes research data will be presented at the American College of Cardiology’s… read more.

Merck to showcase new cardiovascular research at ACC 25, including phase 3 ZENITH trial results

Written by | 21 Mar 2025

Merck known as MSD outside of the United States and Canada, announced that new clinical and outcomes research data will be presented at the American College of Cardiology’s… read more.

Welireg (belzutifan) receives first European Commission approval for two indications – Merck

Written by | 23 Feb 2025

Merck, known as MSD outside of the United States and Canada, announced that the European Commission (EC) has conditionally approved Welireg (belzutifan), Merck’s oral hypoxia-inducible factor-2 alpha (HIF-2α)… read more.

CHMP positive for Welireg (belzutifan) to treat von Hippel-Lindau disease and renal cell carcinoma – Merck Inc

Written by | 1 Jan 2025

Merck Inc., ( known as MSD outside of the United States and Canada), announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted… read more.

NMPA (China) approves Welireg (belzutifan), for the treatment of adult patients with von Hippel-Lindau disease – Merck Inc

Written by | 17 Dec 2024

Merck Inc. (known as MSD outside of the United States and Canada), announced that the National Medical Products Administration (NMPA) in China has approved Welireg (belzutifan), for the… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.